Susan Griffin
Adult Health · West Columbia, SCNPI 1891744660
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 51.6% of the total. Reporting peaked in 2021 at $3,721 and has fallen 73.8% since, to $976 in 2025. Among adult health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $37.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Lilly USA, LLC$475
- Insulet Corporation$463
- Amgen$320
- Novo Nordisk$308
- Abbott$219
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$3,67547%
- Food & beverage$4,11753%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $4,030 |
| Lilly USA, LLC | 25 | $475 |
| Insulet Corporation | 17 | $463 |
| Amgen | 18 | $320 |
| Novo Nordisk | 17 | $308 |
| Abbott | 11 | $219 |
| AbbVie | 12 | $192 |
| Tandem Diabetes Care, Inc. | 9 | $191 |
| Corcept Therapeutics | 10 | $187 |
| Xeris Pharmaceuticals, Inc. | 8 | $162 |
| AstraZeneca(2 entities) | 8 | $158 |
| Sanofi-aventis U.S. LLC | 7 | $156 |
| Ascensia Diabetes Care US Inc. | 5 | $109 |
| BETA Bionics, Inc. | 3 | $83 |
| IBSA Pharma Inc. | 3 | $72 |
| Boehringer Ingelheim | 5 | $70 |
| Cequr Corporation | 2 | $69 |
| Amneal Pharmaceuticals LLC | 3 | $65 |
| Antares Pharma, Inc. | 4 | $64 |
| Dexcom, Inc. | 3 | $58 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Novartis | 2 | $47 |
| Rhythm Pharmaceuticals, Inc. | 2 | $45 |
| Merck | 2 | $28 |
| Halozyme Inc | 2 | $27 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Radius Health, Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $12 |
| Recordati_rare_diseases_inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 770G System$3,675
- Omnipod$109
How this compares
$7,809 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 270 | $440,894 |
| MounjaroTirzepatide | 105 | $153,119 |
| TrulicityDulaglutide | 58 | $99,261 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $91,288 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $75,764 |
| JardianceEmpagliflozin | 60 | $74,453 |
| FarxigaDapagliflozin Propanediol | 65 | $57,864 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $50,203 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $50,135 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $42,700 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $37,982 |
| Novolog FlexpenInsulin Aspart | 75 | $30,790 |
| Humalog Kwikpen U-100Insulin Lispro | 84 | $29,886 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $28,896 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $21,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $308 | $440,894270 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $475 | $260,047209 claims |
| Boehringer IngelheimJardiance | $70 | $74,45360 claims |
| AstraZenecaFarxiga | $158 | $57,86465 claims |
| MerckJanuvia, Janumet Xr | $28 | $19,54825 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $65 | $84856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.
Other adult health in West Columbia
- Andrea OlsonWest Columbia$12K
- Christi WigginsWest Columbia$10K
- Leslee AunWest Columbia$8K
- Jennifer PeaglerWest Columbia$8K
- Latoya HintonWest Columbia$7K
- Shannon HallmanWest Columbia$7K
- Natalie O'KellyWest Columbia$7K
- Haleigh TaylorWest Columbia$6K
- Cecilia PorcherWest Columbia$6K
- Kaitlyn KeenanWest Columbia$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.